Dyne Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript - Thomson StreetEvents

Dyne Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Dyne Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript - Thomson StreetEvents
Dyne Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Published Sep 05, 2024
10 pages (6683 words) — Published Sep 05, 2024
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of DYN.OQ presentation 5-Sep-24 8:05pm GMT

  
Brief Excerpt:

...Great, thank you. Thanks, Mike. Well, as usual, going to be making some forward-looking statements, but before we do that I actually want to talk not about forward, but maybe about the last week and get in front of a few of the questions and be transparent about it. Earlier in the week, we had presented in advance of this conference information about executive changes. And we had also announced information about our DMD program. And frankly, we timed it so that we could have more conversations here. Really to be very transparent, I think we overloaded people with information. And the effect of that was that, in my view, some of the lead messages and stories got buried. And I was quite, really in some ways, surprised and a bit disappointed that the stock had taken a hit. I know it's been recovering and that seems appropriate. But I do want to get to a couple of messages and be really clear about it. One of the headlines was that several executives had resigned. And I think the expression...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Dyne Therapeutics Inc
Ticker
DYN.OQ
Time
8:05pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Michael Ulz - Morgan Stanley - Analyst : No, that was a good introduction and clarified a couple of things. Maybe a few follow-ups. Maybe just one on the leadership changes. Are there any plans to make future changes or are we kind of in the right spot for now? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 05, 2024 / 8:05PM, DYN.OQ - Dyne Therapeutics Inc at Morgan Stanley Global Healthcare Conference

Question: Michael Ulz - Morgan Stanley - Analyst : Maybe we can just switch to the DMD data. And you brought it up, just the two patients that experience the safety. Can you maybe just give us a little bit more details on that and why that is or isn't concerning?

Question: Michael Ulz - Morgan Stanley - Analyst : Maybe just a quick follow-up. Just given that it's considered most likely unrelated, you've obviously dropped the dose, but are there other things you can do to maybe mitigate this potential risk in the future? Or any thoughts around that?

Question: Michael Ulz - Morgan Stanley - Analyst : Could you decide to go up on the dose in the future and what might be some of the considerations that lead you to do that?

Question: Michael Ulz - Morgan Stanley - Analyst : Can you maybe talk about just next steps from the program from here and when we might get another update?

Question: Michael Ulz - Morgan Stanley - Analyst : Makes sense. How do you think about expanding beyond exon 51 into sort of other exon?

Question: Michael Ulz - Morgan Stanley - Analyst : John, you talked about rapidly sort of advancing the program. Maybe just talk commercially. I know we're a little bit away from that, but just the impact of gene therapy and how exon skippers can kind of fit into that paradigm?

Question: Michael Ulz - Morgan Stanley - Analyst : Makes sense. Maybe we can shift gears a little bit just to DM1. And I think you're going to present an update later this year. So maybe just kind of remind us what you've shown so far and what we should expect.

Question: Michael Ulz - Morgan Stanley - Analyst : Maybe just quickly, last minute, just the current thinking on the regulatory path forward. I know you're going to give us specifics, but just what are kind of the options at this point?

Question: Michael Ulz - Morgan Stanley - Analyst : Okay, great. We're out of time, unfortunately. Thanks so much, John, Doug, and Wildon. Really appreciate your time.

Table Of Contents

Dyne Therapeutics Inc Topline Clinical Results from the DELIVER Trial of Z-Rostudirsen DYNE-251 in Duchenne Muscular Dystrophy Transcript – 2025-12-08 – US$ 54.00 – Edited Transcript of DYN.OQ conference call or presentation 8-Dec-25 1:00pm GMT

Dyne Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript – 2025-09-08 – US$ 54.00 – Edited Transcript of DYN.OQ presentation 8-Sep-25 1:15pm GMT

Dyne Therapeutics Inc Update on DYNE-101 for Myotonic Dystrophy Type 1 Conference Call Transcript – 2025-06-17 – US$ 54.00 – Edited Transcript of DYN.OQ conference call or presentation 17-Jun-25 12:00pm GMT

Dyne Therapeutics Inc at JPMorgan Healthcare Conference Transcript – 2025-01-15 – US$ 54.00 – Edited Transcript of DYN.OQ presentation 15-Jan-25 6:30pm GMT

Dyne Therapeutics Inc ACHIEVE Clinical Update Transcript – 2025-01-10 – US$ 54.00 – Edited Transcript of DYN.OQ corporate analyst meeting</ 10-Jan-25 1:00pm GMT

Dyne Therapeutics Inc DELIVER Clinical Update Transcript – 2024-09-03 – US$ 54.00 – Edited Transcript of DYN.OQ corporate analyst meeting</ 3-Sep-24 12:00pm GMT

Dyne Therapeutics Inc at JPMorgan Healthcare Conference Transcript – 2024-01-09 – US$ 54.00 – Edited Transcript of DYN.OQ presentation 9-Jan-24 10:15pm GMT

Dyne Therapeutics Inc at Jefferies CNS & Neuro Summit Transcript – 2023-10-12 – US$ 54.00 – Edited Transcript of DYN.OQ presentation 12-Oct-23 1:30pm GMT

Dyne Therapeutics Inc at Chardan Genetic Medicines Conference Transcript – 2023-10-03 – US$ 54.00 – Edited Transcript of DYN.OQ presentation 3-Oct-23 3:00pm GMT

Dyne Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript – 2023-09-11 – US$ 54.00 – Edited Transcript of DYN.OQ presentation 11-Sep-23 8:15pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Dyne Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript" Sep 05, 2024. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Dyne-Therapeutics-Inc-at-Morgan-Stanley-Global-Healthcare-Conference-T16111958>
  
APA:
Thomson StreetEvents. (2024). Dyne Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript Sep 05, 2024. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Dyne-Therapeutics-Inc-at-Morgan-Stanley-Global-Healthcare-Conference-T16111958>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.